BioCryst Pharmaceuticals Inc
Veridion Score
Composite trend over time
Why is BCRX moving today?
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for BCRX.
BCRX insider activity
BioCryst Pharmaceuticals Inc
6 insiders bought in the last 90 days
Net selling: -$4.8M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-02 | 2026-05-29 | McKee Amy E | Insider | buy | $8.91 | 631 | 31,883 | $6K | SEC Form 4 |
| 2026-06-02 | 2026-05-29 | Milne Jill C. | Insider | buy | $8.91 | 1,262 | 16,644 | $11K | SEC Form 4 |
| 2026-06-02 | 2026-05-29 | Frank Steven | Insider | buy | $8.91 | 1,262 | 20,165 | $11K | SEC Form 4 |
| 2026-06-02 | 2026-05-29 | Stonehouse Jon P | Insider | buy | $8.91 | 631 | 1,324,481 | $6K | SEC Form 4 |
| 2026-06-02 | 2026-05-29 | MILANO VINCENT | Insider | buy | $8.91 | 1,122 | 93,189 | $10K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 39 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moBCRX contract awards, year to date.
Public federal awards linked to this ticker.
BCRX lobbying filings, year to date.
Registered lobbying filings matched to BioCryst Pharmaceuticals Inc.